18 C
New York
Friday, May 20, 2022

Paige Launches Artificial Intelligence Software for Accurate and Efficient Detection of Breast Cancer Metastases in Lymph Nodes

- Advertisement -
- Advertisement -

Paige Breast Lymph Node improves diagnostic accuracy and reliability in detecting breast cancer metastases in lymph node tissue

AI software detects whether breast cancer has metastasized to lymph nodes based on interpretive review by pathologists

NEW YORK, March 24, 2022–(BUSINESS WIRE)–Paige, the global leader in AI-based pathology diagnostic software, today launched its latest product, Paige Breast Lymph Node, an AI medical device software that enables pathologists, according to their own interpretive review, determine if breast cancer has metastasized to the lymph nodes*. The product was presented at the annual meeting of the Academy of Pathology of the United States and Canada (USCAP), held from March 19 to 24, 2022.

This press release contains multimedia content. See the full announcement here: https://www.businesswire.com/news/home/20220322006218/en/

Paige Breast Lymph Node is designed to increase accuracy and efficiency in detecting breast cancer metastases that are most at risk of going undetected. (Photo: Paige)

Determining whether breast cancer has spread to the lymphatic system is critical to a patient’s diagnosis and treatment plan. Due to the size of the tissue area and the size of small micrometastases, accurate evaluation of a lymph node by pathologists can be tedious and time consuming.

Paige Breast Lymph Node increases accuracy and efficiency in detecting breast cancer metastases, which are most at risk of going undetected. AI will enable pathologists to more efficiently and reliably detect tumor metastases of any size, including small micrometastases. The software is designed to improve diagnostic accuracy for even the most subtle foci of metastases and has a slide sensitivity of over 98 percent to detect metastases of any size. Thanks to the TissueMap developed by Paige, it is possible to show a positive indication of metastatic breast cancer for the corresponding lymph node, while highlighting all regions of the slide with suspected cancer. In addition, both slides and cases with suspected positive lymph nodes are highlighted, allowing pathologists to efficiently prioritize and review them.

“Accurate detection of breast cancer metastases is extremely important for physicians and their patients, but can be a tedious and manual task for pathologists,” said David Klimstra, MD, Paige’s founder and chief medical officer. “Paige Breast Lymph Node provides pathologists with a faster and more efficient way to analyze large volumes of lymph node tissue and peace of mind for them and their patients.”

Paige Breast Lymph Node is now available as part of the Paige Breast Suite. The software leverages Paige Prostate’s underlying AI technology and works with a wide range of data, staining methods, and scanning artifacts, resulting in generalizable AI that can be rapidly deployed in a variety of laboratory and hospital settings. .

“The Paige Breast Lymph Node reinforces the value of the Paige Breast Suite for clinical pathologists,” said Andy Moye, Ph.D., CEO of Paige – Expanding the platform into new disease areas. Along with our FDA-approved product, Paige Prostate, the generalizability of AI validates the broader use of Paige software to help pathologists diagnose cancer.”

Paige will host a webinar on March 30 to demonstrate how the Paige Breast Lymph Node can be used in clinical practice. For more information on Paige’s mammary lymph node, visit http://info.paige.ai/breast or email [email protected]

*Paige Breast Lymph Node is available for investigational use only in the US and other regions where investigational use is permitted. Research-only products should not be used for diagnostic procedures.

About Paige

Paige was founded in 2017 by Thomas Fuchs, MD, David Klimstra, MD, and their colleagues at Memorial Sloan Kettering Cancer Center (MSK). The company develops computer-aided pathology products that enable patients and medical teams to make more informed and effective treatment decisions. Recognizing that this new class of AI-based technologies will drive the future of diagnostics, Paige has created a platform that provides pathologists with this novel technology to transform their workflows and increase diagnostic confidence and productivity. Paige’s products provide pathologists and oncologists with insights so they can efficiently make more accurate diagnoses for their patients. Paige is the first company to receive FDA approval for an AI-based digital pathology product.

For more information visit: https://www.paige.ai, Twitter and LinkedIn.

The source language in which the original text is published is the official and authorized version. Translations will be included for better understanding. Only the version in the language that was originally published is legally valid. Therefore, compare the translations with the original language version of the publication.

View the original version on businesswire.com: https://www.businesswire.com/news/home/20220322006218/en/


jon yu
ICR Westwicke
Phone: 475.395.5375
[email protected]

Source link

- Advertisement -

New Articles